(Q33322308)

25 July 2017

title

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome (English)

1 reference

magnetic resonance imaging

25 July 2017

main subject

0 references

Michael G Dwyer

5

0 references

Robert Zivadinov

series ordinal

1

object named as

Robert Zivadinov

1 reference

25 July 2017

Milena Stosic

2

1 reference

25 July 2017

Jennifer L Cox

series ordinal

3

1 reference

25 July 2017

Deepa P Ramasamy

series ordinal

4

1 reference

25 July 2017

publication date

1 March 2008

1 reference

25 July 2017

1 reference

25 July 2017

volume

255 Suppl 1

1 reference

25 July 2017

page(s)

61-74

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-008-1009-1

25 July 2017

exact match

0 references

cites work

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-1009-1

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-1009-1

Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-1009-1

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-1009-1

Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-1009-1

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

21 January 2018

1 reference

12 December 2020

MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Abstracts of the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 10th Annual Meeting of Rehabilitation in Multiple Sclerosis, September 28-October 1, 2005, Thessaloniki, Greece

1 reference

12 December 2020

Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis.

1 reference

12 December 2020

Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.

1 reference

12 December 2020

Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.

1 reference

12 December 2020

Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis?

1 reference

12 December 2020

Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis.

1 reference

12 December 2020

Enhanced magnetic resonance imaging in multiple sclerosis

1 reference

12 December 2020

Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?

1 reference

12 December 2020

Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images

1 reference

12 December 2020

Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla

1 reference

12 December 2020

T1 hypointensities and axonal loss

1 reference

12 December 2020

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

1 reference

12 December 2020

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

1 reference

12 December 2020

Widespread demyelination in the cerebellar cortex in multiple sclerosis.

1 reference

12 December 2020

Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results.

1 reference

12 December 2020

Clinical-magnetic resonance imaging correlations in multiple sclerosis

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 reference

12 December 2020

Resolution-dependent estimates of multiple sclerosis lesion loads

1 reference

12 December 2020

Remyelination is extensive in a subset of multiple sclerosis patients.

1 reference

12 December 2020

Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR.

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Implementation and evaluation of a new pulse sequence for rapid acquisition of double inversion recovery images for simultaneous suppression of white matter and CSF.

1 reference

12 December 2020

Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion.

1 reference

12 December 2020

Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.

1 reference

12 December 2020

Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla.

1 reference

12 December 2020

A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

1 reference

12 December 2020

Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions

1 reference

12 December 2020

Measuring in vivo myelination of human white matter fiber tracts with magnetization transfer MR.

1 reference

12 December 2020

Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients.

1 reference

12 December 2020

Multiple sclerosis: new insights and trends.

1 reference

12 December 2020

Magnetic resonance imaging measures of brain atrophy in multiple sclerosis

1 reference

12 December 2020

The measurement and clinical relevance of brain atrophy in multiple sclerosis

1 reference

12 December 2020

1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study

1 reference

12 December 2020

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies

1 reference

12 December 2020

Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging

1 reference

12 December 2020

In vivo evaluation of remyelination in rat brain by magnetization transfer imaging

1 reference

12 December 2020

Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation

1 reference

12 December 2020

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

12 December 2020

A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis.

1 reference

12 December 2020

Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging.

1 reference

12 December 2020

Functional MRI in multiple sclerosis

1 reference

12 December 2020

Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.

1 reference

12 December 2020

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

1 reference

12 December 2020

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study.

1 reference

12 December 2020

Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology

1 reference

12 December 2020

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

Role of MRI in multiple sclerosis I: inflammation and lesions

1 reference

12 December 2020

Central nervous system atrophy and clinical status in multiple sclerosis

1 reference

12 December 2020

10.1007/S00415-008-1009-1

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

1028891295

0 references

1 reference